DENVER, Feb. 10, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share…


Previous articlePsychedelics Weekly – AIMS vs. the DEA: An Update on the Fight to Reschedule Psilocybin
Next articleSilo Pharma Announces Filing of Patent for Treatment of Alzheimer’s